HSCSJuly 29, 2026 at 1:00 PM UTCHealth Care Equipment & Services

HeartSciences Files Preliminary Proxy for Fortitude Merger, Keeping Deal on Track Amid Financial Peril

Read source article

What happened

HeartSciences Inc. filed its preliminary proxy statement for the business combination with Fortitude Mining Holdings, a crucial step that keeps the reverse-merger timeline on track ahead of the October 31 waiver deadline. The company also touted the commercial launch of its MyoVista Insights platform and the FDA submission of its MyoVista wavECG device, though these milestones remain overshadowed by a dire cash position and going-concern warning. The proxy filing reduces near-term timeline risk, but the underlying investment thesis—that legacy HSCS holders will be diluted to a ~5% post-close stake in an unproven Zcash mining operation—remains intact. Market attention now shifts to shareholder vote support and the threat of pre-close dilutive financing, which could further erode remaining equity value. While the merger progress is a procedural positive, it does not resolve the deep structural challenges facing current shareholders.

Implication

The preliminary proxy reduces the immediate risk of a timeline blowup, yet the investment case remains highly speculative. Legacy shareholders face near-total dilution post-merger, and the value proposition depends entirely on Fortitude’s unproven mining economics. Before closing, HSCS must secure shareholder approval and navigate its liquidity crunch without resorting to toxic financing. Even if the deal completes, the ~5% residual stake means upside is capped unless Zcash mining significantly outperforms aggressive projections. We maintain our POTENTIAL SELL rating and would only reconsider if post-close solrate data or ZEC price materially exceed expectations.

Thesis delta

The preliminary proxy filing marks the first concrete step toward closing, slightly reducing the probability of a bearish timeline slip. However, it does not alter the extreme post-close dilution for legacy holders or the binary risk of deal failure. The rating remains POTENTIAL SELL with a trim above $4.80.

Confidence

High